These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 16900391)

  • 1. The mTOR pathway in breast cancer.
    Hynes NE; Boulay A
    J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):53-61. PubMed ID: 16900391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
    Carraway H; Hidalgo M
    Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status and challenges associated with targeting mTOR for cancer therapy.
    Dowling RJ; Pollak M; Sonenberg N
    BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin: a new molecular target for breast cancer.
    Mita MM; Mita A; Rowinsky EK
    Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
    Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin: master regulator of cell growth in the nervous system.
    Sandsmark DK; Pelletier C; Weber JD; Gutmann DH
    Histol Histopathol; 2007 Aug; 22(8):895-903. PubMed ID: 17503347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy.
    Papadimitrakopoulou V; Adjei AA
    J Thorac Oncol; 2006 Sep; 1(7):749-51. PubMed ID: 17409953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian target of rapamycin (mTOR) Inhibitors.
    Dutcher JP
    Curr Oncol Rep; 2004 Mar; 6(2):111-5. PubMed ID: 14751088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Hidalgo M; Rowinsky EK
    Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
    Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O
    Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An expanding role for mTOR in cancer.
    Guertin DA; Sabatini DM
    Trends Mol Med; 2005 Aug; 11(8):353-61. PubMed ID: 16002336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the mTOR pathway using deforolimus in cancer therapy.
    Mahalingam D; Sankhala K; Mita A; Giles FJ; Mita MM
    Future Oncol; 2009 Apr; 5(3):291-303. PubMed ID: 19374536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.
    Vincenzi B; Napolitano A; D'Onofrio L; Frezza AM; Silletta M; Venditti O; Santini D; Tonini G
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1685-705. PubMed ID: 22010859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Gibbons JJ; Abraham RT; Yu K
    Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent clinical trials of mTOR-targeted cancer therapies.
    Don AS; Zheng XF
    Rev Recent Clin Trials; 2011 Jan; 6(1):24-35. PubMed ID: 20868343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.